Management of HER2-Low Metastatic Breast Cancer: A Comprehensive Statement by an Expert Group from the Middle East and Africa Region

Approximately 50 to 67% of breast cancers (BCs), traditionally categorized as human epidermal growth factor receptor 2 (HER2)-negative, but demonstrating low HER2 expression, are now being defined as a new HER2-low subset or HER2-low category of BC. For metastatic BC (mBC), standard therapy options...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Shaheenah Dawood, Mohsen Mokhtar, Ahmed Alwbari, Bernardo Rapoport, Ece Esin, Hassan Jaafar, Jamal Zekri, Narjiss Berrada, Ozgur Ozyilkan, Nagi El Saghir
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Shiraz University of Medical Sciences 2025-10-01
Edice:	Middle East Journal of Cancer
Témata:	breast neoplasms her2-low immunoconjugates trastuzumab deruxtecan sacituzumab govitecan
On-line přístup:	https://mejc.sums.ac.ir/article_50590_31ce17421f15ccce87c42b6fa6221037.pdf
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!